Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]

• मुख्य लेखकों: Ranzenigo M (लेखक), Gianotti N (लेखक), Galli L (लेखक), Poli A (लेखक), Mastrangelo A (लेखक), Bruzzesi E (लेखक), Chiurlo M (लेखक), Nozza S (लेखक), Bossolasco S (लेखक), Spagnuolo V (लेखक), Mancusi D (लेखक), Termini R (लेखक), Carini E (लेखक), Lazzarin A (लेखक), Castagna A (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Dove Medical Press, 2022-10-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Ranzenigo M, Gianotti N, Galli L, et al. Drug Des Devel Ther. 2022;16:1975–1982. Page 1975, Abstract, Results, line five, the text “the ongoing regimen was based on NNRTIs in 37 (35%) and on InSTIs in 69 (65%)” should read “the ongoing regimen was based on NNR...